440 related articles for article (PubMed ID: 32061596)
1. Therapeutic Landscape for NAFLD in 2020.
Neuschwander-Tetri BA
Gastroenterology; 2020 May; 158(7):1984-1998.e3. PubMed ID: 32061596
[TBL] [Abstract][Full Text] [Related]
2. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
3. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.
Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K
Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219
[TBL] [Abstract][Full Text] [Related]
4. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
Lazaridis N; Tsochatzis E
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
[TBL] [Abstract][Full Text] [Related]
5. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis for current targets of NASH therapies.
Qureshi K; Neuschwander-Tetri BA
Expert Opin Investig Drugs; 2020 Feb; 29(2):151-161. PubMed ID: 31847612
[No Abstract] [Full Text] [Related]
7. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.
Milic S; Mikolasevic I; Krznaric-Zrnic I; Stanic M; Poropat G; Stimac D; Vlahovic-Palcevski V; Orlic L
Drug Des Devel Ther; 2015; 9():4835-45. PubMed ID: 26316717
[TBL] [Abstract][Full Text] [Related]
8. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
9. A Critical Approach of Guideline Therapeutic Recommendations for NAFLD.
Djordjevic DB; Zdravkovic M; Nagorni A; Manolis A; Tsioufis C; Lovic D
Curr Vasc Pharmacol; 2018; 16(3):228-238. PubMed ID: 28676026
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
Gottlieb A; Mosthael W; Sowa JP; Canbay A
Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
12. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
Wree A; Mehal WZ; Feldstein AE
Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
[TBL] [Abstract][Full Text] [Related]
13. Future trends in the treatment of non-alcoholic steatohepatitis.
Fiorucci S; Biagioli M; Distrutti E
Pharmacol Res; 2018 Aug; 134():289-298. PubMed ID: 30021122
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
15. NASH: A glance at the landscape of pharmacological treatment.
Brodosi L; Marchignoli F; Petroni ML; Marchesini G
Ann Hepatol; 2016; 15(5):673-81. PubMed ID: 27493105
[TBL] [Abstract][Full Text] [Related]
16. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.
Noureddin M; Mato JM; Lu SC
Exp Biol Med (Maywood); 2015 Jun; 240(6):809-20. PubMed ID: 25873078
[TBL] [Abstract][Full Text] [Related]
19. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.
Della Pepa G; Vetrani C; Lombardi G; Bozzetto L; Annuzzi G; Rivellese AA
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28954437
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for Nonalcoholic Fatty Liver Disease.
Gawrieh S; Chalasani N
Semin Liver Dis; 2015 Aug; 35(3):338-48. PubMed ID: 26378648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
